Women's Health Reports (Feb 2022)

The CHRONOS Real-World Evidence of Biologic Treatments in Psoriatic Arthritis in Italy: A Post Hoc Gender Analysis

  • Delia Colombo,
  • Micol Frassi,
  • Giuseppa Pagano Mariano,
  • Enrico Fusaro,
  • Claudia Lomater,
  • Patrizia Del Medico,
  • Florenzo Iannone,
  • Rosario Foti,
  • Massimiliano Limonta,
  • Antonio Marchesoni,
  • Bernd Raffeiner,
  • Ombretta Viapiana,
  • Marco Di Carlo,
  • Rosa Daniela Grembiale,
  • Giuliana Guggino,
  • Paola Faggioli,
  • Enrico Tirri,
  • Roberto Perricone,
  • Pier Carlo Sarzi Puttini,
  • Salvatore De Vita,
  • Fabrizio Conti,
  • Sara Rizzoli,
  • Barbara Roncari,
  • Martina Fiocchi,
  • Roberto Orsenigo,
  • Emanuela Zagni,
  • Collaboration group,
  • Collaboration group,
  • Frassi Micol,
  • Caminiti Maurizio,
  • Fusaro Enrico,
  • Lomater Claudia,
  • Del Medico Patrizia,
  • Iannone Fiorenzo,
  • Foti Rosario,
  • Limonta Massimiliano,
  • Marchesoni Antonio,
  • Raffeiner Bernd,
  • Viapiana Ombretta,
  • Grassi Walter,
  • Grembiale Rosa Daniela,
  • Guggino Giuliana,
  • Mazzone Antonino,
  • Tirri Enrico,
  • Perricone Roberto,
  • Sarzi Puttini Pier Carlo,
  • De Vita Salvatore,
  • Conti Fabrizio

DOI
https://doi.org/10.1089/WHR.2021.0063
Journal volume & issue
Vol. 3, no. 1
pp. 162 – 171

Abstract

Read online

Background: Phenotypic features and outcome differences between sexes have been reported in psoriatic arthritis (PsA). However, little is known about sex differences in effectiveness of biologics in clinical practice. Methods: Post hoc gender analysis of the CHRONOS, a multicenter, noninterventional, retroprospective Italian real-world study assessing 6-month and 1-year effectiveness of biologics for PsA. Results: Eligible patients were 399, 43.1% men. Sociodemographic characteristics, type of arthritis, baseline Disease Activity Score 28 joints (DAS28), and duration of biologic treatment were rather homogeneous. More men were overweight/obese and naive to biologics. The most frequently used biologics were TNF-inhibitors and secukinumab in both sexes. DAS28 responders were 72.7% (women) and 70.5% (men) at 6 months, and 68.0% in both sexes at 1 year. American College of Rheumatology (ACR) response showed a trend for men versus women to achieve more frequently ACR50 (32.6% vs. 26.5% at 6 months; 34.9% vs. 20.0% at 1 year) and ACR70 (22.3% vs. 12.4% at 6 months and 25.0% vs. 13.0% at 1 year). Global satisfaction with treatment at enrollment and after 6 months was slightly higher among men [mean (standard deviation) Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) score: 68.6 (18.6) and 69.9 (18.2), respectively] than women [65.3 (18.2), 66.2 (18.5)]. Conclusions: Overall response to biologics for PsA was rather favorable. With similar baseline disease severity, men appear to have a somewhat earlier and better response with higher treatment satisfaction.

Keywords